Compare Alcon AG (ALC) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Nucor Corporation — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Nucor Corporation trades at $225.87 (market cap $51.79B). The key difference: Nucor Corporation is the larger of the two by market cap, and Nucor Corporation pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| ALC | NUE | |
|---|---|---|
Market Cap | $32.69B | $51.79B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $266.35 |
52-Week Low | $62.02 | $131.78 |
Enterprise Value | $36.28B | $56.44B |
Dividend Yield | 0.54% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Nucor (NUE) trades at $227.42, up 3.02% over the past day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with 59% analyst buy ratings but faces declining revenue and net income from 2022 peaks. Recent developments include a joint venture to support AI power infrastructure and a consistent dividend history, with Q2 2026 EPS guidance projecting growth.
Outlook remains cautiously optimistic due to strong analyst targets averaging $260.75 and operational expansions, though risks include steel demand volatility and compressed profit margins. The stock's valuation at a P/E of 22.21 appears reasonable if earnings rebound as projected in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
